secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protalix BioTherapeutics, Inc. (PLX)
CIK:        0001006281
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0001558370-23-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Protalix updates on PRX-102 FDA PDUFA date May 9, 2023; PRX-115 Phase I in Q1 2023
--------------------------------------------------------------------------------

- MAA submitted to EMA Feb 2022; BLA resubmitted to FDA Nov 2022 with PDUFA goal date May 9, 2023.
- BALANCE study: PRX-102 statistically non-inferior to agalsidase beta on eGFR slope; BRIGHT: stable disease.
- PRX-115 (PEGylated uricase) for severe gout: Phase I trial planned for Q1 2023; preclinical data show stable PK and low immunogenicity.
- If PRX-102 approved by FDA, Protalix eligible for milestone payment from partner Chiesi.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023000003/0001558370-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1006281/000155837023000003/plx-20230103x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer